Orencia SC deal marks shift in Simcere's BMS alliance
This article was originally published in Scrip
Executive Summary
China's Simcere Pharmaceutical sees the latest expansion of its strategic partnership with Bristol-Myers Squibb as helping both to build up its portfolio of innovative products and to enhance its presence in rheumatoid arthritis (RA).